GSK-3beta

GSK-3beta Informations sur la molécule

Nom anglais	Glycogen synthase kinase-3 beta	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	4	Alias de la cible	EC 2.7.11，EC:2.7.11.26，EC:2.7.11.1，Serine/threonine-protein kinase GSK3B，Glycogen synthase kinase-3 beta，GSK3B，Glycogen Synthase Kinase 3 Beta，GSK-3 Beta，GSK3beta Isoform，EC 2.7.11.26，EC 2.7.11.1
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Glycogen synthase kinase-3 beta
Alias de la cible	EC 2.7.11，EC:2.7.11.26，EC:2.7.11.1，Serine/threonine-protein kinase GSK3B，Glycogen synthase kinase-3 beta，GSK3B，Glycogen Synthase Kinase 3 Beta，GSK-3 Beta，GSK3beta Isoform，EC 2.7.11.26，EC 2.7.11.1
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	4
Phase de R&D la plus avancée	Phase 3 Clinical

GSK-3beta Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
GSB-H5545	Human	InsectCells	Human GSK-3beta / GSK-3β Protein, His Tag (active enzyme, MALS verified)				Ajouter au panier

Quantité totale1

GSK-3betaContexte de la molécule

Glycogen synthase kinase-3 (GSK-3) is a pivotal molecule in the development of Alzheimer's disease (AD). GSK-3beta is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.

GSK-3betaAlias de la molécule

GSK3B,Glycogen synthase kinase-3 beta

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Tideglusib	NP-12; AMO-02; NP-031112	Phase 3 Clinical	Noscira Sa	Alzheimer Disease; Amyotrophic Lateral Sclerosis; Autism Spectrum Disorder; Cardiomyopathies; Myotonic Dystrophy	Details
Ruboxistaurin Mesilate Hydrate	LY-333531; REC 3599; SM 030	Phase 2 Clinical	Eli Lilly And Company	Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Gangliosidoses, GM2; Heart Failure; Hyperpigmentation; Melanosis	Details
Elraglusib	9-ING-41	Phase 2 Clinical	Actuate Therapeutics Inc, Northwest University, University Of Illinois At Chicago	Adenocarcinoma; Bone metastases; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Dermatofibrosarcoma; Diffuse Intrinsic Pontine Glioma; Glioma; Hemangiosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia-Lymphoma, Adult T-Cell; Liposarcoma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Meningioma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Osteosarcoma; Pancreatic Neoplasms; Primary Myelofibrosis; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial	Details
Asnuciclib	CDKI-73; LS-007; QHRD-107	Phase 2 Clinical	Shandong University, University Of South Australia	Leukemia, Myeloid, Acute	Details